{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:24Z","timestamp":1756425744053,"version":"3.44.0"},"reference-count":36,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:p>Many people consulting dermatologists for nail problems have a fungal nail infection (onychomycosis). This may be asymptomatic and not merit prolonged treatment, particularly since relapse after such intervention is common.1\u20133 On the other hand, fungal nail infection is sometimes a treatable risk factor for more serious bacterial infections including cellulitis.4 Here we discuss the management of adults with fungal nail infection.<\/jats:p>","DOI":"10.1136\/dtb.2007.12.0007","type":"journal-article","created":{"date-parts":[[2008,1,2]],"date-time":"2008-01-02T11:13:27Z","timestamp":1199272407000},"page":"3-8","source":"Crossref","is-referenced-by-count":2,"title":["How should fungal nail infection be treated?"],"prefix":"10.1136","volume":"46","member":"239","published-online":{"date-parts":[[2008,1,2]]},"reference":[{"key":"2025082723221418000_46.1.3.1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2133.2003.05242.x","article-title":"Guidelines for treatment of onychomycosis.","volume":"148","author":"Roberts","year":"2003","journal-title":"Br J Dermatol"},{"key":"2025082723221418000_46.1.3.2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05242.x"},{"key":"2025082723221418000_46.1.3.3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.353"},{"key":"2025082723221418000_46.1.3.4","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1551"},{"key":"2025082723221418000_46.1.3.5","doi-asserted-by":"publisher","DOI":"10.1159\/000080853"},{"key":"2025082723221418000_46.1.3.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80215-0"},{"key":"2025082723221418000_46.1.3.7","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2006.00056"},{"key":"2025082723221418000_46.1.3.8","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"key":"2025082723221418000_46.1.3.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00109.x"},{"key":"2025082723221418000_46.1.3.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03673.x"},{"key":"2025082723221418000_46.1.3.11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.10.1279"},{"key":"2025082723221418000_46.1.3.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1992.tb00276.x"},{"key":"2025082723221418000_46.1.3.13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2133.149.s65.2.x","article-title":"Combination therapy for onychomycosis.","volume":"149","author":"Olafsson","year":"2003","journal-title":"Br J Dermatol"},{"key":"2025082723221418000_46.1.3.14","unstructured":"Joint Formulary Committee. British National Formulary Edition 54 London: Royal Pharmaceutical Society of Great Britain and British Medical Association September 2007."},{"key":"2025082723221418000_46.1.3.15","unstructured":"Lamisil tablets 250mg Summary of product characteristics UK: Novartis Pharmaceuticals UK Limited February 2007."},{"key":"2025082723221418000_46.1.3.16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/bmj.318.7190.1031","article-title":"Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis.","volume":"318","author":"Evans","year":"1999","journal-title":"BMJ"},{"key":"2025082723221418000_46.1.3.17","unstructured":"Sporanox capsules Summary of product characteristics UK: Janssen-Cilag Ltd March 2004."},{"key":"2025082723221418000_46.1.3.18","unstructured":"Sporanox-Pulse Summary of product characteristics UK: Janssen-Cilag Ltd November 2002."},{"key":"2025082723221418000_46.1.3.19","unstructured":"Loceryl nail lacquer 5% Summary of product characteristics UK: Galderma (UK) Limited August 2006."},{"key":"2025082723221418000_46.1.3.20","unstructured":"Curanail 5% nail lacquer Summary of product characteristics UK: Galderma (UK) Limited August 2006."},{"key":"2025082723221418000_46.1.3.21","unstructured":"Trosyl nail solution Summary of product characteristics UK: Pfizer Limited May 2004."},{"key":"2025082723221418000_46.1.3.22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2133.2003.05728.x","article-title":"Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.","volume":"150","author":"Gupta","year":"2004","journal-title":"Br J Dermatol"},{"key":"2025082723221418000_46.1.3.23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05728.x"},{"key":"2025082723221418000_46.1.3.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.055"},{"key":"2025082723221418000_46.1.3.25","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.110644"},{"key":"2025082723221418000_46.1.3.26","doi-asserted-by":"publisher","DOI":"10.1159\/000247612"},{"key":"2025082723221418000_46.1.3.27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001434.pub2"},{"key":"2025082723221418000_46.1.3.28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1046\/j.1365-2133.2000.03545.x","article-title":"A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.","volume":"142","author":"Baran","year":"2000","journal-title":"Br J Dermatol"},{"key":"2025082723221418000_46.1.3.29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03545.x"},{"key":"2025082723221418000_46.1.3.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.145s60021.x"},{"key":"2025082723221418000_46.1.3.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07974.x"},{"key":"2025082723221418000_46.1.3.32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1439-0507.2006.01351.x","article-title":"Onychomycosis.","volume":"50","author":"Seebacher","year":"2007","journal-title":"Mycoses"},{"key":"2025082723221418000_46.1.3.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01351.x"},{"key":"2025082723221418000_46.1.3.34","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690050022003"},{"key":"2025082723221418000_46.1.3.35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0190-9622(00)90129-4","article-title":"Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases.","volume":"42","author":"Tosti","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2025082723221418000_46.1.3.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90129-4"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2007.12.0007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:22:23Z","timestamp":1756362143000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2007.12.0007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,1,2]]},"published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1136\/dtb.2007.12.0007"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2007.12.0007","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}